Table 1.
Metabolic Syndrome Definitions
| Old NCEP | Revised NCEP | WHO | IDF | EGIR | Consensus IDF* | |
|---|---|---|---|---|---|---|
| Metabolic syndrome definition | Any three of the following five | Any three of the following five | ↑Fasting glucose or >75th percentile HOMA + two of the following | Abdominal obesity+two of the following | Fasting insulin >75th percentile + any two of the following | Any three of the following five |
| Abdominal obesity/BMI | Waist >102/88 cm | Waist >102/88 cm and >90/80 cm in Chinese | WHR >0.9/0.85 in males/females and/or BMI >30 | Race specific cutoffs† | Waist >94/80 cm in all races | Race specific cutoffs† |
| Hypertension | BP ≥135/80 mmHg or treatment | BP ≥135/80 mmHg or treatment | BP ≥140/90 mmHg or treatment | BP ≥140/90 mmHg or treatment | BP ≥140/90 mmHg or treatment | BP ≥135/80 mmHg or treatment |
| Triglycerides | ≥150 mg/dL | ≥150 mg/dL or treatment | ≥150 mg/dL or treatment | ≥150 mg/dL or treatment | ≥177.1 mg/dL or treatment and/or | ≥150 mg/dL or treatment |
| HDL | <40/50 mg/dL (M/F) | <40/50 mg/dL (M/F) or treatment | <35/40 mg/dL (M/F) or treatment | <40/50 mg/dL in (M/F) or treatment | <40 mg/dL or treatment | <40/50 mg/dL (M/F) or treatment |
| Fasting glucose | ≥110 mg/dL | ≥100 mg/dL | ≥110 mg/dL | ≥100 mg/dL | 100–126 mg/dL | ≥100 mg/dL |
| Fasting insulin | — | — | — | — | >8 mU/L | — |
| HOMA-IR | — | — | >1.837 | — | — | — |
| UAC ratio | — | — | ≥30 mg/g | — | — | — |
†Waist >94/80 cm in caucasians and African-American (M/F), 90/80 cm in Chinese and Hispanics (M/F).
*
Consensus AHA same as consensus IDF except higher cutoffs for caucasians (>102/88 cm).
NCEP, National Cholesterol Education Program; WHO, World Health Organization; IDF, International Diabetes Federation; EGIR, European Group for the Study of Insulin Resistance; HOMA, homeostasis model assessment; BMI, body mass index; WHR, waist-to-hip ratio; BP, blood pressure; HDL, high-density lipoprotein; M, male; F, female; IR, insulin resistance; UAC, urine albumin–creatinine ratio.